Contribution of serotonergic and nitrergic pathways, as well as monoamine oxidase-a and Na+, K+-ATPase enzymes in antidepressant-like action of ((4-tert-butylcyclohexylidene) methyl) (4-methoxystyryl) sulfide (BMMS)

• Published in: Metabolic brain disease Vol. 34; no. 5; pp. 1313 - 1324
• Main Authors: de Oliveira, Renata L., Voss, Guilherme T., Paltian, Jaini J., Pinz, Mikaela P., Torres, Marina Laura C. P., Moreira, Michele P., Dilelio, Marina C., Silveira, Claudio C., Wilhelm, Ethel A., Luchese, Cristiane
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.10.2019; Springer Nature B.V
• Subjects: Amine oxidase (flavin-containing); Animals; Antidepressants; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Arginine; Arginine - pharmacology; Behavior, Animal - drug effects; Biochemistry; Biomedical and Life Sciences; Biomedicine; Depression - drug therapy; Depression - metabolism; Disease Models, Animal; Dizocilpine; Excitatory Amino Acid Antagonists - pharmacology; Fluoxetine; Fluoxetine - pharmacology; Fluoxetine - therapeutic use; Glutamatergic transmission; Glutamic acid receptors (ionotropic); Hindlimb Suspension; Ketanserin; Male; Metabolic Diseases; Mice; Monoamine Oxidase - metabolism; Motor Activity - drug effects; N-Methyl-D-aspartic acid receptors; Na+/K+-exchanging ATPase; Neurology; Neurosciences; Nitric oxide; Nitric Oxide - metabolism; Oncology; Original Article; Oxidase; Prefrontal cortex; Prefrontal Cortex - drug effects; Prefrontal Cortex - metabolism; Serotonin; Serotonin - metabolism; Serotonin Antagonists - pharmacology; Serotonin S1 receptors; Serotonin S2 receptors; Serotonin S3 receptors; Sodium-Potassium-Exchanging ATPase - metabolism; Styrenes - pharmacology; Styrenes - therapeutic use; Sulfide; Sulfides; Sulfides - pharmacology; Sulfides - therapeutic use; Na; Monoamine oxidase; Serotonin; Nitric oxide; ATPase; Depression; K; Sulfur; Na+; K+-ATPase
• ISSN: 0885-7490; 1573-7365
• DOI: 10.1007/s11011-019-00436-x

The present study investigated a possible antidepressant-like effect of ((4- tert -butylcyclohexylidene)methyl) (4-methoxystyryl) sulfide (BMMS) by using the forced swimming test (FST) and the tail suspension test (TST) in Swiss mice. The contribution of serotoninergic, glutamatergic and nitrergic systems in the antidepressant-like activity of BMMS was evaluated. We also examined the involvement of monoamine oxidase (MAO)-A, MAO-B and Na + , K + -ATPase activities in prefrontal cortex of mice. BMMS, (0.1–10 mg/kg, intragastrically (i.g.)) and fluoxetine (32 mg/kg, i.g.) decreased the immobility time in the FST and TST. The anti-immobility effect of BMMS (10 mg/kg, i.g.) in the TST was prevented by the pretreatment of mice with WAY100635 (0.1 mg/kg, subcutaneously (s.c.), a 5-HT 1A receptor antagonist), ketanserin (5 mg/kg, intraperitoneal (i.p.), a 5-HT 2A/2C receptor antagonist), and partially blocked by ondansetron (1 mg/kg, i.p., a 5-HT 3 receptor antagonist). The anti-immobility effect of BMMS (10 mg / kg, i.g.) was not avoided by pretreatment with MK-801 (0.01 mg/kg, s.c. a non-competitive N-methyl D-Aspartate (NMDA) receptor) in the TST. Pretreatment with L-arginine (500 mg/kg, i.p., a nitric oxide precursor) reversed partially the reduction in the immobility time elicited by BMMS (10 mg/kg, i.g.) in TST. BMMS altered Na + ,K + -ATPase and MAO-A activities in prefrontal cortex of mice, but was not able to change the MAO-B activity. In conclusion, BMMS exerted an antidepressant-like effect in mice and serotonergic and nitrergic systems are involved in the antidepressant-like action of compound. BMMS modulated MAO-A and Na + , K + - ATPase activities in prefrontal cortex of mice.